These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2685956

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Overview of current preclinical testing strategies for viral vaccines.
    Wood DJ.
    Dev Biol Stand; 1998; 95():19-23. PubMed ID: 9855410
    [No Abstract] [Full Text] [Related]

  • 4. Vaccinia virus vectors.
    Moss B.
    Biotechnology; 1992; 20():345-62. PubMed ID: 1600384
    [No Abstract] [Full Text] [Related]

  • 5. Non-target effects of live vaccines: myth, reality and demagoguery.
    Levine MM.
    Dev Biol Stand; 1995; 84():33-8. PubMed ID: 7796965
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of live pseudorabies virus vaccines.
    Kimman TG, Gielkens AL, Glazenburg K, Jacobs L, de Jong MC, Mulder WA, Peeters BP.
    Dev Biol Stand; 1995; 84():89-96. PubMed ID: 7796972
    [No Abstract] [Full Text] [Related]

  • 9. 2nd forum in virology. Vaccinia-vectored vaccines--risks and benefits.
    Res Virol; 1989; 140(5):461-91. PubMed ID: 2587850
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The influence of recombination on the genetic stability of pseudorabies vaccine virus.
    Visser N.
    Dev Biol Stand; 1995; 84():97-104. PubMed ID: 7796973
    [No Abstract] [Full Text] [Related]

  • 12. Regulatory issues relating to the use of recombinant vectors in production of human vaccines.
    Marcus-Sekura CJ.
    Dev Biol Stand; 1994; 82():107-12. PubMed ID: 7958464
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Peroral immunization--a method for enhancing the safety of the recombinant vector (the vaccinia virus)].
    Podkuĭko VN, Vorob'ev AA, Krasnianskiĭ VP, Patrikeev GT, Mikhaĭlov VV, Dorokhina TV, Makhlaĭ AA, Dykanov GA.
    Vestn Ross Akad Med Nauk; 1993; (2):39-44. PubMed ID: 7688619
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
    Ober BT, Brühl P, Schmidt M, Wieser V, Gritschenberger W, Coulibaly S, Savidis-Dacho H, Gerencer M, Falkner FG.
    J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
    [Abstract] [Full Text] [Related]

  • 16. A view on regulatory aspects of live viral vaccine safety.
    Horaud F.
    Dev Biol Stand; 1994 Aug; 82():113-8. PubMed ID: 7958465
    [Abstract] [Full Text] [Related]

  • 17. Vaccinia-vectored vaccines for exotic disease immunization programmes.
    Dalrymple JM.
    Res Virol; 1989 Aug; 140(5):477-80. PubMed ID: 2587853
    [No Abstract] [Full Text] [Related]

  • 18. How do vaccinia-vectored vaccines fit into animal immunization programmes?
    Brown F.
    Res Virol; 1989 Aug; 140(5):474-6. PubMed ID: 2685957
    [No Abstract] [Full Text] [Related]

  • 19. [Control of vaccines, especially viral vaccines].
    Lafontaine A.
    Arch Inst Pasteur Alger; 1986 Aug; 55():257-67. PubMed ID: 3079513
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.